G. De, L. Fluvastatine-eg, . Mylan, R. Qualimed, and S. Section, mises en garde et précautions d'emploi Interaction alimentaire : pas d'interaction avec le jus de pamplemousse Étant donné l'absence d'interaction de la fluvastatine avec d'autres substrats du CYP3A4

S. Shurin, S. B. , E. Nabel, P. For, and . Time, Pharmacogenomics ??? Ready for Prime Time?, New England Journal of Medicine, vol.358, issue.10, pp.1061-1063, 2008.
DOI : 10.1056/NEJMe0800801

K. Nakagawa, T. Ishizaki, T. Relevance, . Pharmacogenetic, . In et al., Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine, Pharmacology & Therapeutics, vol.86, issue.1, pp.1-28, 2000.
DOI : 10.1016/S0163-7258(99)00066-2

H. Schelleman, I. Between, . Candidates, . And, . Drug et al., Interactions between five candidate genes and antihypertensive drug therapy on blood pressure, The Pharmacogenomics Journal, vol.21, issue.1, pp.22-26, 2006.
DOI : 10.1097/00004872-200301000-00017

URL : http://www.nature.com/tpj/journal/v6/n1/pdf/6500339a.pdf

A. Beitelshees, I. Of, . And, . On-?-blockers, . Drug et al., Influence of phenotype and pharmacokinetics on ??-blocker drug target pharmacogenetics, The Pharmacogenomics Journal, vol.353, issue.3, pp.174-178, 2006.
DOI : 10.1016/S0140-6736(99)00549-8

J. Mialet-perez, . Receptor, . Confer, . Function, . Predisposition et al., ??1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure, Nature Medicine, vol.86, issue.suppl. 1, pp.1300-1304, 2003.
DOI : 10.1161/01.RES.86.8.834

G. , A. Of, . In, . With, . Dose et al., The Lancet, pp.717-724, 1999.